Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine

ABINGDON, England & RIO DE JANEIRO--(BUSINESS WIRE)--Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T cell immune response, and researchers at the Institute of Technology on Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), today announce the determination of the MHC CD8 T cell epitope expression library for Fiocruz’s commercial yellow feve